Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia.

Literature DB >> 6294831

Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia.

P L Faris, B R Komisaruk, L R Watkins, D J Mayer.

Abstract

The endogenous neuropeptide cholecystokinin, when administered systemically or perispinally, potently antagonizes opiate analgesia produced by foot shock and morphine. Nonopiate foot-shock analgesia is not reduced by this neuropeptide. The spinal cord appears to be a critical site of cholecystokinin action. These experiments suggest a physiological role for cholecystokinin as a specific opiate antagonist in analgesia-mediating systems. A similar mode of action may explain other behavioral effects of cholecystokinin, such as suppression of food intake.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 1983 PMID： 6294831 DOI： 10.1126/science.6294831

Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728

Keyword Cloud
Cited

61 in total

1. Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.

Authors: Kaleeckal G Harikumar; Eyup Akgün; Philip S Portoghese; Laurence J Miller
Journal: J Med Chem Date: 2010-04-08 Impact factor: 7.446

2. Attenuation of the morphine withdrawal syndrome by inhibition of catabolism of endogenous enkephalins in the periaqueductal gray matter.

Authors: R Maldonado; M C Fournié-Zaluski; B P Roques
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1992-04 Impact factor: 3.000

3. Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.

Authors: Yeon Sun Lee; Richard S Agnes; Hamid Badghisi; Peg Davis; Shou-wu Ma; Josephine Lai; Frank Porreca; Victor J Hruby
Journal: J Med Chem Date: 2006-03-09 Impact factor: 7.446

4. Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.

Authors: M A Coudoré-Civiale; M Méen; M C Fournié-Zaluski; M Boucher; B P Roques; A Eschalier
Journal: Br J Pharmacol Date: 2001-05 Impact factor: 8.739

5. Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.

Authors: Yeon Sun Lee; Richard S Agnes; Peg Davis; Shou-wu Ma; Hamid Badghisi; Josephine Lai; Frank Porreca; Victor J Hruby
Journal: J Med Chem Date: 2007-01-11 Impact factor: 7.446

10. Transient expression of the cholecystokinin gene in male germ cells and accumulation of the peptide in the acrosomal granule: possible role of cholecystokinin in fertilization.

Authors: H Persson; J F Rehfeld; A Ericsson; M Schalling; M Pelto-Huikko; T Hökfelt
Journal: Proc Natl Acad Sci U S A Date: 1989-08 Impact factor: 11.205

Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia.

1. Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.

2. Attenuation of the morphine withdrawal syndrome by inhibition of catabolism of endogenous enkephalins in the periaqueductal gray matter.

3. Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.

4. Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.

5. Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.

Review 6. Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain.

7. Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor.

8. Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation.

9. Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine.

10. Transient expression of the cholecystokinin gene in male germ cells and accumulation of the peptide in the acrosomal granule: possible role of cholecystokinin in fertilization.